Patents Assigned to Aventis Pharma Ltd.
-
Publication number: 20090114219Abstract: An inhaler device (1) contains, or is capable of accepting, a plurality of doses of a medicament to be dispensed from the inhaler (1). To ameliorate the problem of double dosing from the inhaler (1), the device further comprises prevention means (26, 28, 40) for preventing, at least temporarily, the dispensing of a dose of medicament, and detection means (32) for detecting the inhalation of a previously dispensed dose of medicament. When the detection means (32) detects the inhalation of the previously dispensed dose of medicament, it releases the prevention means (26, 28, 40), allowing the device to dispense a further dose of medicament. The detection means (32) may be a pressure sensor, and the prevention means (26, 28, 40) may operate by causing a disengagement of an actuation mechanism.Type: ApplicationFiled: April 7, 2006Publication date: May 7, 2009Applicant: AVENTIS PHARMA LTDInventors: Christopher Ferris, Matthew Young, Jonathan Oakley, Wayne O'Hara
-
Patent number: 7001993Abstract: Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid sequence of natural human antithrombin is substituted by another amino acid. Preferable examples thereof are human antithrombin variants wherein the amino acid at position 78 is substituted by Phe; the amino acid at position 278 is substituted by Ala, Arg, Asn, Gly, His, Tyr or Val; the amino acid at position 378 is substituted by Lys, Asn or Val; and/or the amino acid at position 380 is substituted by Ala, Asp, Gly, His, lie, Leu, Asn, Pro, Arg, Thr, Tyr or Val.Type: GrantFiled: June 22, 2000Date of Patent: February 21, 2006Assignee: Aventis Pharma Ltd.Inventor: Takehiko Koide
-
Patent number: 6632814Abstract: The invention is directed to physiologically active compounds of formula (I): wherein R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C2-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)—R9, —N(R8)—C(═O)—OR9, —N(RType: GrantFiled: August 23, 2000Date of Patent: October 14, 2003Assignees: Aventis Pharma Ltd., Aventis Pharmaceuticals Recherche DeveloppmentInventors: Jean-Dominique Bourzat, Alain Commercon, Bruno Jacques Christophe Filoche, Neil Victor Harris, Thomas David Pallin, Keith Alfred James Stuttle
-
Patent number: 6620832Abstract: The invention is directed to physiologically active compounds of general formula (I): wherein R1 is lower alkyl, R2 is aryl, arylalkyl, heteroaryl or heteroarylalkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a cyclic amine, Ar1 is aryldiyl or heteroaryldiyl, Ar2 is optionally substituted phenylene or heteroaryldiyl, L1 is an a —R5—R6— linkage where R5 is alkylene, alkenylene or alkynylene and R6 is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, —C(═Z1)—NR4—, —NR4—C(═Z1)—, —Z1—, —C(═O)—, —C(═NOR4)—, —NR4—, —NR4—C(═Z1)—NR4—, —SO2—NR4—, —NR4—SO2—, —O—C(═O)—, —C(═O)—O—, —NR4—C(═O)—O— or —O—C(═O)—NR4—, L2 is a direct bond, an optionally substituteType: GrantFiled: November 2, 2001Date of Patent: September 16, 2003Assignee: Aventis Pharma Ltd.Inventor: Paul Robert Eastwood
-
Patent number: 6608084Abstract: The invention is directed to physiologically active compounds of formula (I) wherein R1 represents R3—Z3—, R3—L2—R4—Z3—, R3—L3—Ar1—L4—Z3— or R3—L3—Ar1—L2—R4—Z3—; R2 represents hydrogen, halogen, lower alkyl or lower alkoxy; A1 represents a straight chain C1-3alkylene linkage optionally substituted by one or more groups chosen from alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, imino, oxo, thioxo, or alkyl substituted by —ZR6, —NY1Y2, —CO2R6 or —C(═O)—NY1Y2; L1 represents a direct bond; an alkenylene, alkylene, alkynylene, cycloalkenylene, cycloalkylene, heteroaryldiyl, heterocycloalkylene or arylene linkage each optionally substituted by (a) an acidic functional group, cyano, oxo, —S(O)mR9, R3, —C(═O)—R3, —C(═O)—OR3, —N(R8)—C(═O)R9, —N(R8)—SO2—R9, —NY4Y5 or —[CType: GrantFiled: October 17, 2001Date of Patent: August 19, 2003Assignees: Aventis Pharma Ltd., Aventis Recherche DeveloppmentInventors: Jean-Dominique Bourzat, Alain Commercon, Bruno Jacques Christophe Filoche, Neil Victor Harris, Clive McCarthy